Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country

Mycoses

Volumn 60, Issue 3, 2017, Pages 198-203

  Ulu Kilic, Aysegul ^a   Alp, Emine ^a   Cevahir, Fatma ^a   Ture, Zeynep ^a   Yozgat, Nuran ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

candida; candidemia; cost; defined daily doses; developing country

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE; ECHINOCANDIN; LIPOPEPTIDE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL THERAPY; ARTICLE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; CHILD; DEVELOPING COUNTRY; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CANDIDA; CANDIDA ALBICANS; CROSS INFECTION; DRUG EFFECTS; ECONOMICS; EPIDEMIOLOGICAL MONITORING; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TURKEY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DEVELOPING COUNTRIES; ECHINOCANDINS; EPIDEMIOLOGICAL MONITORING; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LENGTH OF STAY; LIPOPEPTIDES; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TURKEY; YOUNG ADULT;

EID: 85001790710     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12582     Document Type: Article

References (18)

1. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(Suppl 2):S87–S91.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.
3. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816–2823.
4. Ma CF, Li FQ, Shi LN, et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis. 2013;13:337.
5. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A, French Candidemia Study G. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect. 2002;8:405–412.
6. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40:1303–1312.
7. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002;40:3489–3492.
8. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10.
9. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–332.
10. WHO Collaborating Centre for Drug Statistics Methodology (WHOCC): DDD Definition and general considerations.
11. Ulu-Kilic A, Alp E, Cevahir F, et al. Economic evaluation of appropriate duration of antibiotic prophylaxis for prevention of neurosurgical infections in a middle-income country. Am J Infect Control. 2015;43:44–47.
12. Ulu-Kilic A, Ozhan E, Altun D, Percin D, Gunes T, Alp E. Is it worth screening for vancomycin-resistant Enterococcus faecium colonization?: financial burden of screening in a developing country. Am J Infect Control. 2016;44:e45–e49.
13. Alp S, Arikan-Akdagli S, Gulmez D, Ascioglu S, Uzun O, Akova M. Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses. 2015;58:498–505.
14. Kazak E, Akin H, Ener B, et al. An investigation of Candida species isolated from blood cultures during 17 years in a university hospital. Mycoses. 2014;57:623–629.
15. Marcos-Zambrano LJ, Escribano P, Sanchez C, Munoz P, Bouza E, Guinea J. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother. 2014;58:4565–4572.
16. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493–2499.
17. Guillot J, Lebel D, Roy H, Ovetchkine P, Bussieres JF. Usefulness of defined daily dose and days of therapy in pediatrics and obstetrics-gynecology: a comparative analysis of antifungal drugs (2000-2001, 2005-2006, and 2010-2011). J Pediatr Pharmacol Ther. 2014;19:196–201.
18. Sendid B, Cotteau A, Francois N, et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis. 2006;6:80.